Cell-Based Treatment in Acute Myeloid Leukemia Relapsed after Allogeneic Stem Cell Transplantation

被引：1

作者：

Canichella, Martina ^{[1
]}

de Fabritiis, Paolo ^{[1
,2
]}

机构：

[1] St Eugenio Hosp, ASL Roma2, Haematol Unit, Rome, Italy

[2] Tor Vergata Univ, Dept Biomed & Prevent, I-00133 Rome, Italy

来源：

BIOMEDICINES | 2024年 / 12卷 / 08期

关键词：

acute myeloid leukemia (AML); allogeneic stem cell transplantation (ASCT); cellular therapy; donor lymphocyte infusion (DLI); chimeric antigen receptor (CAR)-T cells; next-generation CAR-T cells; universal CAR-T (UCAR-T); UniCAR technology; CHIMERIC ANTIGEN RECEPTOR; DONOR LYMPHOCYTE INFUSION; CAR-T-CELLS; INDUCED KILLER-CELLS; LEUKOCYTE INFUSIONS; RISK-FACTORS; AML PATIENTS; IMMUNOTHERAPY; THERAPY; ADULTS;

D O I：

10.3390/biomedicines12081721

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Allogeneic stem cell transplant (ASCT) remains the only treatment option for patients with high-risk acute myeloid leukemia (AML). Recurrence of leukemic cells after ASCT represents a dramatic event associated with a dismal outcome, with a 2-year survival rate of around 20%. Adoptive cell therapy (ACT) is a form of cell-based strategy that has emerged as an effective therapy to treat and prevent post-ASCT recurrence. Lymphocytes are the principal cells used in this therapy and can be derived from a hematopoietic stem cell donor, the patient themselves, or healthy donors, after being engineered to express the chimeric antigen receptor (CAR-T and UniCAR-T). In this review, we discuss recent advances in the established strategy of donor lymphocyte infusion (DLI) and the progress and challenges of CAR-T cells.

引用

页数：16

共 84 条

[31] CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia [J].

Kenderian, S. S. ;

Ruella, M. ;

Shestova, O. ;

Klichinsky, M. ;

Aikawa, V. ;

Morrissette, J. J. D. ;

Scholler, J. ;

Song, D. ;

Porter, D. L. ;

Carroll, M. ;

June, C. H. ;

Gill, S. .

LEUKEMIA, 2015, 29 (08) :1637-1647

[32] CAR-NK Cells: From Natural Basis to Design for Kill [J].

Khawar, Muhammad Babar ;

Sun, Haibo .

FRONTIERS IN IMMUNOLOGY, 2021, 12

[33] Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy [J].

Kittel-Boselli, Enrico ;

Soto, Karla Elizabeth Gonzalez ;

Loureiro, Liliana Rodrigues ;

Hoffmann, Anja ;

Bergmann, Ralf ;

Arndt, Claudia ;

Koristka, Stefanie ;

Mitwasi, Nicola ;

Kegler, Alexandra ;

Bartsch, Tabea ;

Berndt, Nicole ;

Altmann, Heidi ;

Fasslrinner, Frederick ;

Bornhaeuser, Martin ;

Bachmann, Michael Philipp ;

Feldmann, Anja .

CANCERS, 2021, 13 (19)

[34] DONOR LEUKOCYTE TRANSFUSIONS FOR TREATMENT OF RECURRENT CHRONIC MYELOGENOUS LEUKEMIA IN MARROW TRANSPLANT PATIENTS [J].

KOLB, HJ ;

MITTERMULLER, J ;

CLEMM, C ;

HOLLER, E ;

LEDDEROSE, G ;

BREHM, G ;

HEIM, M ;

WILMANNS, W .

BLOOD, 1990, 76 (12) :2462-2465

[35] Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML [J].

Legrand, F. ;

Le Floch, A-C ;

Granata, A. ;

Fuerst, S. ;

Faucher, C. ;

Lemarie, C. ;

Harbi, S. ;

Bramanti, S. ;

Calmels, B. ;

El-Cheikh, J. ;

Chabannon, C. ;

Weiller, P-J ;

Vey, N. ;

Castagna, L. ;

Blaise, D. ;

Devillier, R. .

BONE MARROW TRANSPLANTATION, 2017, 52 (04) :620-621

[36] Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation [J].

Levine, JE ;

Braun, T ;

Penza, SL ;

Beatty, P ;

Cornetta, K ;

Martino, R ;

Drobyski, WR ;

Barrett, AJ ;

Porter, DL ;

Giralt, S ;

Leis, J ;

Holmes, HE ;

Johnson, M ;

Horowitz, M ;

Collins, RH .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) :405-412

[37] A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CART cells and gilteritinib [J].

Li, Ke-xin ;

Wu, Hui-yang ;

Pan, Wan-ying ;

Guo, Meng-qi ;

Qiu, De-zhi ;

He, Yan-jie ;

Li, Yu-hua ;

Yang, Dong-Hua ;

Huang, Yu-xian .

MOLECULAR CANCER, 2022, 21 (01)

[38] CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype [J].

Li, Saisai ;

Tao, Zhongfei ;

Xu, Yingxi ;

Liu, Jia ;

An, Na ;

Wang, Ying ;

Xing, Haiyan ;

Tian, Zheng ;

Tang, Kejing ;

Liao, Xiaolong ;

Rao, Qing ;

Wang, Min ;

Wang, Jianxiang .

HUMAN GENE THERAPY, 2018, 29 (05) :626-639

[39] Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed/refractory acute myeloid leukemia [J].

Lin, Guoqiang ;

Zhang, Yanming ;

Yu, Lei ;

Wu, Depei .

MOLECULAR MEDICINE REPORTS, 2021, 23 (03)

[40] Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing [J].

Liu, Jie ;

Zhou, Guangyu ;

Zhang, Li ;

Zhao, Qi .

FRONTIERS IN IMMUNOLOGY, 2019, 10

← 1 2 3 4 5 6 7 8 9 →